Univariable analysis of OS, EFS, GVHD, GRFS, grade 2 to 4 aGVHD, and cGVHD, stratified by baseline characteristics
| . | OS (95% CI) . | EFS (95% CI) . | GRFS (95% CI) . | aGVHD grade 2-4 (95% CI) . | aGVHD grade 3-4 (95% CI) . | cGVHD (95% CI) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-y OS . | P value . | 5-y EFS . | P value . | 5-y GRFS . | P value . | Day-100 aGVHD . | P value . | Day-100 aGVHD . | P value . | 5-y cGVHD . | P value . | |
| Year of transplant | .6 | .5 | .3 | .03 | .9 | .2 | ||||||
| Before 2014 (n = 396) | 83% (79-87) | 78% (73-82) | 69% (64-74) | 26% (22-30) | 12% (9-15) | 14% (10-18) | ||||||
| After 2014 (n = 417) | 84% (80-88) | 78% (74-83) | 72% (67-77) | 20% (16-24) | 13% (9-16) | 10% (7-13) | ||||||
| Age at transplant | .009 | <.001 | .2 | .07 | .09 | |||||||
| <10 y (n = 507) | 86% (83-89) | 83% (79-86) | 76% (72-80) | <.001 | 21% (18-25) | 11% (8-13) | 10% (7-13) | |||||
| ≥10 y (n = 306) | 78% (73-83) | 70% (65-76) | 61% (55-67) | 26% (21-31) | 15% (11-19) | 15% (10-20) | ||||||
| Interval between diagnosis and transplant | .6 | .7 | .7 | .2 | .3 | >.99 | ||||||
| <12 mo (n = 242) | 81% (75-86) | 78% (72-83) | 69% (63-76) | 20% (15-25) | 10% (6-14) | 11% (7-13) | ||||||
| 12-24 mo (n = 143) | 87% (90-93) | 81% (74-88) | 74% (65-82) | 21% (14-28) | 11% (6-17) | 13% (6-20) | ||||||
| >24 mo (n = 428) | 83% (80-87) | 77% (73-81) | 70% (65-75) | 26% (21-30) | 14% (11-17) | 12% (8-16) | ||||||
| Sex | .6 | .3 | .4 | .7 | .8 | .9 | ||||||
| Male (n = 415) | 84% (80-88) | 80% (75-84) | 72% (67-77) | 24% (20-28) | 12% (9-15) | 12% (8-15) | ||||||
| Female (n = 394) | 83% (79-87) | 76% (72-81) | 69% (64-74) | 23% (18-27) | 13% (9-16) | 12% (8-16) | ||||||
| Indication for transplant | <.001 | <.001 | <.001 | .03 | >.99 | .4 | ||||||
| BMF/AA (n = 778) | 85% (83-88) | 80% (77-83) | 72% (69-76) | 22% (19-25) | 12% (10-15) | 12% (10-15) | ||||||
| AML/MDS (n = 35) | 40% (23-57) | 33% (17-49) | 32% (15-49) | 38% (22-55) | 12% (1-23) | 7% (0-15) | ||||||
| Donor | <.001 | <.001 | <.001 | <.001 | <.001 | .12 | ||||||
| MFD (n = 441) | 88% (85-91) | 85% (81-89) | 80% (76-85) | 17% (14-21) | 8% (5-11) | 10% (7-14) | ||||||
| MUD (n = 162) | 86% (80-91) | 80% (73-86) | 69% (62-77) | 29% (22-36) | 15% (10-21) | 15% (9-21) | ||||||
| MMFD/MMUD (n = 144) | 72% (64-80) | 62% (54-71) | 49% (39-58) | 36% (28-44) | 24% (17-32) | 16% (9-23) | ||||||
| HID (n = 66) | 70% (59-82) | 62% (50-74) | 58% (46-70) | 19% (9-28) | 8% (1-15) | 8% (1-14) | ||||||
| Stem cell source | .02 | .3 | .6 | .3 | .7 | .08 | ||||||
| Marrow (n = 526) | 86% (83-89) | 80% (76-83) | 72% (68-76) | 22% (18-26) | 13% (10-16) | 10% (7-13) | ||||||
| Peripheral blood (n = 226) | 79% (74-85) | 77% (71-83) | 68% (62-75) | 26% (20-32) | 12% (7-16) | 16% (10-22) | ||||||
| CB (n = 58) | 76% (65-88) | 73% (61-85) | 67% (54-80) | 18% (8-28) | 9% (1-16) | 17% (6-29) | ||||||
| Ex vivo TCD | .1 | .05 | .2 | .3 | .13 | .2 | ||||||
| Yes (n = 87) | 76% (67-86) | 71% (62-81) | 65% (54-76) | 19% (10-27) | 7% (2-12) | 8% (2-15) | ||||||
| No (n = 712) | 84% (81-87) | 79% (76-82) | 72% (68-76) | 23% (20-27) | 13% (10-15) | 13% (10-16) | ||||||
| Conditioning | .003 | .029 | .029 | <.001 | .06 | .013 | ||||||
| FluCy (n = 611) | 86% (83-89) | 80% (77-84) | 73% (69-77) | 17% (14-20) | 10% (8-13) | 10% (7-13) | ||||||
| FluCy + other chemotherapy (n = 63) | 72% (60-84) | 66% (54-78) | 56% (42-70) | 37% (25-49) | 17% (7-26) | 15% (5-25) | ||||||
| Non-FluCy conditioning (n = 133) | 78% (71-86) | 76% (68-84) | 69% (60-77) | 41% (32-50) | 17% (10-24) | 21% (12-29) | ||||||
| Serotherapy | .05 | .2 | .016 | <.001 | <.001 | <.001 | ||||||
| ATG (n = 620) | 82% (79-85) | 76% (72-93) | 69% (64-73) | 23% (20-27) | 13% (11-16) | 12% (9-15) | ||||||
| Alemtuzumab (n = 86) | 93% (88-98) | 86% (79-93) | 85% (77-93) | 7% (2-13) | 0% | 4% (0-8) | ||||||
| None (n = 103) | 82% (74-90) | 81% (73-89) | 68% (57-79) | 35% (26-45) | 17% (9-24) | 24% (14-35) | ||||||
| TBI | .004 | <.001 | .004 | .9 | >.99 | .9 | ||||||
| Yes (n = 96) | 73% (64-82) | 65% (55-75) | 56% (45-67) | 23% (14-32) | 12% (6-19) | 11% (4-18) | ||||||
| No (n = 688) | 85% (82-88) | 80% (77-83) | 73% (69-76) | 23% (20-27) | 12% (10-15) | 12% (9-15) | ||||||
| . | OS (95% CI) . | EFS (95% CI) . | GRFS (95% CI) . | aGVHD grade 2-4 (95% CI) . | aGVHD grade 3-4 (95% CI) . | cGVHD (95% CI) . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-y OS . | P value . | 5-y EFS . | P value . | 5-y GRFS . | P value . | Day-100 aGVHD . | P value . | Day-100 aGVHD . | P value . | 5-y cGVHD . | P value . | |
| Year of transplant | .6 | .5 | .3 | .03 | .9 | .2 | ||||||
| Before 2014 (n = 396) | 83% (79-87) | 78% (73-82) | 69% (64-74) | 26% (22-30) | 12% (9-15) | 14% (10-18) | ||||||
| After 2014 (n = 417) | 84% (80-88) | 78% (74-83) | 72% (67-77) | 20% (16-24) | 13% (9-16) | 10% (7-13) | ||||||
| Age at transplant | .009 | <.001 | .2 | .07 | .09 | |||||||
| <10 y (n = 507) | 86% (83-89) | 83% (79-86) | 76% (72-80) | <.001 | 21% (18-25) | 11% (8-13) | 10% (7-13) | |||||
| ≥10 y (n = 306) | 78% (73-83) | 70% (65-76) | 61% (55-67) | 26% (21-31) | 15% (11-19) | 15% (10-20) | ||||||
| Interval between diagnosis and transplant | .6 | .7 | .7 | .2 | .3 | >.99 | ||||||
| <12 mo (n = 242) | 81% (75-86) | 78% (72-83) | 69% (63-76) | 20% (15-25) | 10% (6-14) | 11% (7-13) | ||||||
| 12-24 mo (n = 143) | 87% (90-93) | 81% (74-88) | 74% (65-82) | 21% (14-28) | 11% (6-17) | 13% (6-20) | ||||||
| >24 mo (n = 428) | 83% (80-87) | 77% (73-81) | 70% (65-75) | 26% (21-30) | 14% (11-17) | 12% (8-16) | ||||||
| Sex | .6 | .3 | .4 | .7 | .8 | .9 | ||||||
| Male (n = 415) | 84% (80-88) | 80% (75-84) | 72% (67-77) | 24% (20-28) | 12% (9-15) | 12% (8-15) | ||||||
| Female (n = 394) | 83% (79-87) | 76% (72-81) | 69% (64-74) | 23% (18-27) | 13% (9-16) | 12% (8-16) | ||||||
| Indication for transplant | <.001 | <.001 | <.001 | .03 | >.99 | .4 | ||||||
| BMF/AA (n = 778) | 85% (83-88) | 80% (77-83) | 72% (69-76) | 22% (19-25) | 12% (10-15) | 12% (10-15) | ||||||
| AML/MDS (n = 35) | 40% (23-57) | 33% (17-49) | 32% (15-49) | 38% (22-55) | 12% (1-23) | 7% (0-15) | ||||||
| Donor | <.001 | <.001 | <.001 | <.001 | <.001 | .12 | ||||||
| MFD (n = 441) | 88% (85-91) | 85% (81-89) | 80% (76-85) | 17% (14-21) | 8% (5-11) | 10% (7-14) | ||||||
| MUD (n = 162) | 86% (80-91) | 80% (73-86) | 69% (62-77) | 29% (22-36) | 15% (10-21) | 15% (9-21) | ||||||
| MMFD/MMUD (n = 144) | 72% (64-80) | 62% (54-71) | 49% (39-58) | 36% (28-44) | 24% (17-32) | 16% (9-23) | ||||||
| HID (n = 66) | 70% (59-82) | 62% (50-74) | 58% (46-70) | 19% (9-28) | 8% (1-15) | 8% (1-14) | ||||||
| Stem cell source | .02 | .3 | .6 | .3 | .7 | .08 | ||||||
| Marrow (n = 526) | 86% (83-89) | 80% (76-83) | 72% (68-76) | 22% (18-26) | 13% (10-16) | 10% (7-13) | ||||||
| Peripheral blood (n = 226) | 79% (74-85) | 77% (71-83) | 68% (62-75) | 26% (20-32) | 12% (7-16) | 16% (10-22) | ||||||
| CB (n = 58) | 76% (65-88) | 73% (61-85) | 67% (54-80) | 18% (8-28) | 9% (1-16) | 17% (6-29) | ||||||
| Ex vivo TCD | .1 | .05 | .2 | .3 | .13 | .2 | ||||||
| Yes (n = 87) | 76% (67-86) | 71% (62-81) | 65% (54-76) | 19% (10-27) | 7% (2-12) | 8% (2-15) | ||||||
| No (n = 712) | 84% (81-87) | 79% (76-82) | 72% (68-76) | 23% (20-27) | 13% (10-15) | 13% (10-16) | ||||||
| Conditioning | .003 | .029 | .029 | <.001 | .06 | .013 | ||||||
| FluCy (n = 611) | 86% (83-89) | 80% (77-84) | 73% (69-77) | 17% (14-20) | 10% (8-13) | 10% (7-13) | ||||||
| FluCy + other chemotherapy (n = 63) | 72% (60-84) | 66% (54-78) | 56% (42-70) | 37% (25-49) | 17% (7-26) | 15% (5-25) | ||||||
| Non-FluCy conditioning (n = 133) | 78% (71-86) | 76% (68-84) | 69% (60-77) | 41% (32-50) | 17% (10-24) | 21% (12-29) | ||||||
| Serotherapy | .05 | .2 | .016 | <.001 | <.001 | <.001 | ||||||
| ATG (n = 620) | 82% (79-85) | 76% (72-93) | 69% (64-73) | 23% (20-27) | 13% (11-16) | 12% (9-15) | ||||||
| Alemtuzumab (n = 86) | 93% (88-98) | 86% (79-93) | 85% (77-93) | 7% (2-13) | 0% | 4% (0-8) | ||||||
| None (n = 103) | 82% (74-90) | 81% (73-89) | 68% (57-79) | 35% (26-45) | 17% (9-24) | 24% (14-35) | ||||||
| TBI | .004 | <.001 | .004 | .9 | >.99 | .9 | ||||||
| Yes (n = 96) | 73% (64-82) | 65% (55-75) | 56% (45-67) | 23% (14-32) | 12% (6-19) | 11% (4-18) | ||||||
| No (n = 688) | 85% (82-88) | 80% (77-83) | 73% (69-76) | 23% (20-27) | 12% (10-15) | 12% (9-15) | ||||||
Kaplan-Meier estimates are given for OS, EFS, and GRFS, with group differences tested by log-rank tests, and CINs are given for all other outcomes, with group differences tested by the Gray test. All estimates are reported with 95% CIs in parentheses.